Bispecific Antibody-derived Cancer Therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
90
NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: May 14, 2021
Completion: Dec 31, 2025
Loading map...